Charles Brenner

Charles Brenner (born October 30, 1961) holds the position of Professor of Metabolic Regulation at University of Helsinki, having been recruited with support of the Research Council of Finland. Prior to this, he held the inaugural Alfred E Mann Family Foundation Chair of the Department of Diabetes & Cancer Metabolism at the Beckman Research Institute of the City of Hope National Medical Center and served as the Roy J. Carver Chair and head of biochemistry at the University of Iowa. Brenner discovered eukaryotic nicotinamide riboside (NR) kinase and nucleosidase pathways to NAD.

Brenner's work includes the first human trial of NR, which demonstrated safe oral availability as an NAD+ precursor.

Education and career Brenner graduated from Wesleyan University with a bachelor's degree in biology in 1983. After working for the biotechnology companies Chiron Corporation and DNAX Research Institute, Brenner attended graduate school at Stanford University School of Medicine. At Stanford he worked with Robert S. Fuller, receiving his Ph.D. in Cancer Biology in 1993. Brenner conducted post-doctoral research at Brandeis University with Gregory Petsko and Dagmar Ringe.

Brenner then joined the faculty at Thomas Jefferson University, where he worked from 1996 to 2003, becoming Director of the Structural Biology & Bioinformatics Program in 2000. He moved to Dartmouth Medical School in 2003, serving as associate director for Basic Sciences at Norris Cotton Cancer Center (now named Dartmouth Cancer Center) from 2003 to 2009. In 2009 he joined the University of Iowa (UI) as Professor and Head of Biochemistry. In 2010 he was awarded the Roy J. Carver Chair of Biochemistry at UI, holding that position until 2020.

In 2020, Brenner joined City of Hope National Medical Center in Duarte, California as the inaugural chair of a new department of diabetes and cancer metabolism created to focus at the intersection of metabolic disturbances with diseases such as cancer and diabetes.

Brenner has been funded by agencies including the March of Dimes, the Bill & Melinda Gates Foundation, the Leukemia & Lymphoma Society, the National Science Foundation the National Institutes of Health and the Sigrid Juselius Foundation. Significant research projects include the role of Ap3A binding in the function of the FHIT tumor suppressor gene, characterization and inhibition of DNA methylation, and discovery of new steps in nicotinamide adenine dinucleotide (NAD) metabolism.

Brenner has developed targeted, quantitative analysis of the NAD+ metabolome and made fundamental contributions to NAD metabolism including discovery of nicotinic acid riboside-dependent NAD synthesis, elucidating the mechanism of synthesis of nicotinic acid adenine dinucleotide phosphate, and discovering multiple conditions in which NAD metabolism is dysregulated in disease.

Brenner is active in translating NR technologies to treat and prevent human conditions that disturb the NAD system including cancer heart failure, central brain injury, inflammation, Brenner's work included the first human trial of NR in 2016, which demonstrated safe oral availability as an NAD+ precursor Though Brenner was the first to show that NR increases SIR2 activity, improves gene silencing, and can extend yeast lifespan, his work has not emphasized sirtuins or nonspecific anti-aging claims and instead emphasizes how NR repairs inflammatory conditions and metabolic stresses that dysregulate NAD+

Examining rodents and their offspring, Brenner has showed that rodent postpartum mothers are under severe metabolic stress to their NAD system. Supplementing rodent mothers with NR increases maternal weight loss, advances juvenile development and provides long lasting neurodevelopmental advantages into adulthood. he identified accumulation of glycerol-3-phosphate and activation of ChREBP as the mechanism of both elevated expression of FGF21 and elevated lipogenic transcription in this rare disease. He was the senior editor of the 2004 book, Oncogenomics: Molecular Approaches to Cancer.

Brenner is both cautious and critical of research that promotes claims of anti-aging and longevity. After writing a favorable review of Steven Austad's book Methuselah's Zoo, he reviewed Lifespan: Why We Age – and Why We Don't Have To by David A. Sinclair, summarizing it as "an influential source of misinformation on longevity, featuring counterfactual claims about longevity genes being conserved between yeast and humans, the existence of supposed activators of these genes, and claimed successful age reversal in mice based on partial reprogramming." Brenner published a major review of sirtuins in 2022 entitled "Sirtuins are not conserved longevity genes".

Educational contributions

In 2012, Brenner and Dagmar Ringe developed pre-medical curriculum recommendations that would be consistent with a revised Medical College Admission Test (MCAT), following a request from the President of the American Society for Biochemistry and Molecular Biology, Suzanne Pfeffer. The recommendations, which include development of inorganic, organic and biochemistry coursework that is more geared toward the chemistry of bioorganic functional groups, have been further refined in academic journals. Brenner's contribution to this area was recognized by the 2016 ASBMB Award for Exemplary Contributions to Education. He currently serves as chief scientific advisor of Niagen Bioscience and NADMED.

Awards 2020, Mary Swartz Rose Senior Investigator Award, American Society for Nutrition 2016, ASBMB Award for Exemplary Contributions to Education, American Society for Biochemistry and Molecular Biology 2013, Fellow, American Association for the Advancement of Science 2007, William E.M. Lands Lectureship, University of Michigan Medical School 1998–2001, New Investigator in the Pharmacological Sciences, Burroughs Wellcome Fund 1998–2000, Basil O'Connor Scholar, March of Dimes Birth Defects Foundation

Selected publications Tiwari, V. Jin, Byungchang; Sun, Olivia; LopezGonzalez, Edwin D. J.; Chen, Min-Hsuan; Wu, Xiwei; Shah, Hardik; Zhang, Andrew; Herman, Mark A.; Spracklen, Cassandra N.; Goodman, Russell P.; Brenner, Charles (November 2025). "Glycerol-3-phosphate activates ChREBP, FGF21 transcription and lipogenesis in citrin deficiency". Nature Metabolism. 7 (11): 2284–2299. doi:10.1038/s42255-025-01399-3. ISSN 2522-5812. PMC 12638245